Pharmaceuticals · GLXO
Pharma - MNC bulk Drugs
from 2,662 today
GlaxoSmithKline Pharmaceuticals delivered a better-than-expected revenue and in-line EBITDA/PAT in 1QFY27, driven by a scaling innovative portfolio and strong growth in general medicines. Considering the limited upside from current levels, we maintain a Neutral stance on the stock with a target price of INR2,870.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
